Menu
  • About RedHill
  • Products
  • Partnering
  • Investors
  • News
  • Contact
  • CAREERS
  • Snapshot

    Corporate Profile

    RedHill Biopharma, established in 2009, is a publicly traded (NASDAQ / TASE: RDHL) specialty biopharmaceutical company, headquartered in Israel, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, including cancer.

    RedHill's pipeline currently includes drugs in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill's drugs are largely derisked and are potentially of lower cost and faster to market than new chemical entities under development.

    RedHill's products are based on several technology platforms and address several disease targets, thus providing for risk diversification.

    RedHill's experienced management team, board of directors and advisory board, based in Israel, the US, Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.

    Stock Quote

    Stock Chart

    Copyright Nasdaq. Minimum 15 minutes delayed.

    Stock Chart

    Copyright Nasdaq. Minimum 15 minutes delayed.